Nilotinib (AMN107), Bcr/Abl tyrosine kinase inhibitor (ab142019)

Overview

  • Product name

    Nilotinib (AMN107), Bcr/Abl tyrosine kinase inhibitor
  • Description

    Potent and selective Bcr/Abl tyrosine kinase inhibitor
  • Biological description

    Potent and selective Bcr/Abl tyrosine kinase inhibitor (IC50 = 15 nM). JAK2/STAT5 inhibitor. Inhibits MDM2 at the post-translational level by inducing MDM2 self-ubiquitination and degradation. Shows antiproliferative and antitumor effects in vivo. Orally active.
  • Purity

    > 99%
  • CAS Number

    641571-10-0
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzamide
  • Molecular weight

    529.52
  • Molecular formula

    C28H22F3N7O
  • PubChem identifier

    644241
  • Storage instructions

    Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months.
  • Solubility overview

    Soluble in DMSO to 10 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES

    CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5
  • Source

    Synthetic

  • Research areas

References

This product has been referenced in:

  • Gallipoli P  et al. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo. Blood : (2014). Read more (PubMed: 24957147) »
  • Zhang H  et al. Inhibition of MDM2 by nilotinib contributes to cytotoxicity in both Philadelphia-positive and negative acute lymphoblastic leukemia. PLoS One 9:e100960 (2014). Read more (PubMed: 24968304) »
  • Schneider M  et al. The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal-Implications for targeted therapies. Urol Oncol : (2014). Read more (PubMed: 24996772) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab142019.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up